Pharmacokinetic Consequences of Pegylation

Author： Hamidi Mehrdad Azadi Amir Rafiei Pedram

ISSN： 1521-0464

Source： Drug Delivery, Vol.13, Iss.6, 2006-12, pp. : 399-409

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Obesity-related physiological changes and their pharmacokinetic consequences

By Cho Sung-Joon

Journal of Pharmaceutical Investigation, Vol. 43, Iss. 3, 2013-06 ,pp. : 161-169

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacokinetic Consequences of PLGA Nanoparticles in Docetaxel Drug Delivery

Pharmaceutical Nanotechnology, Vol. 5, Iss. 1, 2017-03 ,pp. : 3-23

Bentham Science Publishers

Access to resources Recommend Favorite

Induction of Drug Metabolising Enzymes: Pharmacokinetic and Toxicological Consequences in Humans

By Fuhr U.

Clinical Pharmacokinetics, Vol. 38, Iss. 6, 2000-06 ,pp. : 493-504

Adis International

Access to resources Recommend Favorite

Genetic Polymorphism of Organic Anion and Cation Transporters: Pharmacokinetic and Pharmacodynamic Consequences in Pharmacotherapy

Current Pharmacogenomics, Vol. 1, Iss. 4, 2003-12 ,pp. : 245-257

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition

By Dresser G.K.

Clinical Pharmacokinetics, Vol. 38, Iss. 1, 2000-01 ,pp. : 41-57

Adis International

Access to resources Recommend Favorite